RecruitingPhase 1NCT03961243

Lentiviral FIX Gene Therapy

Lentiviral FIX Gene Therapy for Hemophilia B

Sponsor

Shenzhen Geno-Immune Medical Institute

Enrollment

10 participants

Start Date

Jun 1, 2025

Study Type

INTERVENTIONAL

Conditions

Hemophilia B

Summary

This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor IX into patients with hemophilia B, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.

Eligibility

Min Age: 2 YearsMax Age: 65 Years

Inclusion Criteria4

\. Able to provide informed consent and comply with requirements of the study. 2. Males ≥2 years with confirmed diagnosis of hemophilia B (endogenous factor IX ≤2 IU/dL or ≤2% of normal).
\. A minimum average of 4 bleeding events per year requiring episodic treatment of factor IX infusions or prophylactic factor IX infusions.
\. No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein.
\. Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences.

Exclusion Criteria4

\. Significant liver dysfunction as defined by abnormal alanine transaminase, bilirubin and alkaline phosphatase.
\. History of inhibitor against factor IX. 3. Evidence of active hepatitis B or C and currently on antiviral therapy. 4. Have serological evidence of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (subjects who are HIV+ and stable with CD4 count >200/mm3 and undetectable viral load are eligible to enroll).
\. Any evidence of active infection or any immunosuppressive disorder. 6. Participated in a gene transfer trial within the last 6 months or in a clinical trial with an investigational drug within the last 12 weeks.
\. Unable or unwilling to comply with study assessments.

Interested in this trial?

Get notified about updates and connect with the research team.